Aquestive Therapeutics
AQST
52 hedge funds and large institutions have $62.9M invested in Aquestive Therapeutics in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 7 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
73% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 11
13% more funds holding
Funds holding: 46 → 52 (+6)
2.24% more ownership
Funds ownership: 38% → 40.24% (+2.2%)
2% less capital invested
Capital invested by funds: $64.4M → $62.9M (-$1.57M)
4% less call options, than puts
Call options by funds: $1.02M | Put options by funds: $1.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$943K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$533K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$530K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$443K |
| 5 |
D.E. Shaw & Co
New York
|
+$441K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1M |
| 2 |
Renaissance Technologies
New York
|
-$895K |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$646K |
| 4 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$545K |
| 5 |
Morgan Stanley
New York
|
-$254K |
AQST Hedge Fund Activity: Q4 2021 in Review
52 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q4 2021, worth a combined $62.9M — down 2.4% from $64.4M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new AQST positions and 7 closed out — a net gain of 6 holders — while 19 added to existing stakes and 11 trimmed.
The largest buyer was Vanguard Group, adding an estimated $943K. The largest seller was GSA Capital Partners, cutting an estimated $1M.
- 52 institutional investors held Aquestive Therapeutics (AQST) as of Q4 2021, up from 46 in Q3 2021.
- Funds reported $62.9M of Aquestive Therapeutics stock for Q4 2021, down 2.4% quarter-over-quarter.
- 13 funds opened new Aquestive Therapeutics positions in Q4 2021 and 7 closed out, a net change of +6 holders.
- The largest Aquestive Therapeutics buyer in Q4 2021 was Vanguard Group, an estimated $943K added.
- The largest Aquestive Therapeutics seller in Q4 2021 was GSA Capital Partners, an estimated $1M sold.
Based on aggregated 13F filings for Q4 2021.